CMC & ManufacturingLast reviewed May 2026

Control Strategy(Control Strategy)

The planned set of controls, derived from product and process understanding, that ensures process performance and product quality.

Usage Examples

The control strategy linked each CQA to specific in-process and release controls with defined acceptance criteria.
Expanded raw material controls for a newly identified impurity required a Prior Approval Supplement.
Module 3.2.P.5 documented the complete control strategy with rationale for each specification limit.

What is Control Strategy?

A Control Strategy is the comprehensive, planned set of controls — derived from current product and process understanding — that ensures process performance and product quality consistently. It is defined in ICH Q10 and operationalizes the QbD framework by integrating input material controls, process parameter controls, in-process testing, release specifications, and stability monitoring into one coherent quality assurance architecture.

A robust control strategy covers: drug substance and raw material specifications; Critical Process Parameters with defined operating ranges; in-process controls at critical steps; intermediate specifications; drug product specifications; container closure controls; and stability program design. The strategy is built around the Critical Quality Attributes identified from the QTPP, ensuring each CQA has appropriate controls throughout the manufacturing process and product shelf life.

The control strategy is documented primarily in Module 3.2.P.5 (specifications) and Module 3.2.P.3.4 (controls of critical steps) of an eCTD submission. FDA reviewers evaluate whether the control strategy is sufficient to ensure consistent quality — inadequate control strategies are a common source of CMC deficiencies and late-cycle remediation.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH Q8, ICH Q9, ICH Q10.

FDAICHHealth Canada

When This Matters

The control strategy linked each CQA to specific in-process and release controls with defined acceptance criteria.
Expanded raw material controls for a newly identified impurity required a Prior Approval Supplement.
Module 3.2.P.5 documented the complete control strategy with rationale for each specification limit.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

ICH Q8ICH Q9ICH Q10ICH Q11

Frequently Asked Questions

Input material specifications, CPP operating ranges, in-process controls, intermediate specifications, release specifications for drug substance and drug product, analytical method validation, container closure controls, and stability monitoring. Each element contributes to controlling a specific CQA or set of CQAs.

Yes. Post-approval changes — new analytical methods, expanded specifications, tightened CPP ranges based on production experience — all update the control strategy. Changes are managed through CMC change control and may require regulatory filings depending on impact (Annual Report, CBE-30, or Prior Approval Supplement).

Process Validation demonstrates that the control strategy, as designed, delivers consistent product quality. PPQ (Process Performance Qualification) runs are executed within the defined operating ranges of the control strategy and demonstrate reproducible results. The control strategy is the prospective plan; process validation is the demonstration that the plan works.